Jody. Staggs on merger rationale
From Runway Growth Finance Conference Call on Acquisition of SWK Holdings | Oct 10, 2025 · · Investing 101
“Through this merger, shareholders will benefit from the robust platform that Runway and BC Partners Credit have built. The combined entity will have increased capacity to issue larger checks to high-quality names and SWK's core competencies while remaining in Runway's target investment range of $20 million to $45 million.”
On , Jody. Staggs, Chief Executive Officer & President at SWK HOLDINGS CORP, spoke about merger rationale during Runway Growth Finance Conference Call on Acquisition of SWK Holdings | Oct 10, 2025 on Investing 101.
About Jody. Staggs
Jody Staggs, President and CEO of SWK Holdings, participated in a conference call on October 10, 2025, regarding Runway Growth Finance's acquisition of SWK. Staggs stated that SWK is a specialty finance company focused on the healthcare and life science industries, providing minimally diluted financing to small and midsize commercial-stage life science companies. He noted that as of August 2025, SWK had completed financings with 58 parties, deploying $867 million of capital since inception, and that the portfolio had generated mid-teens gross returns on capital. Staggs said the combined entity would have increased capacity to issue larger checks while remaining in Runway's target investment range of $20 million to $45 million. On a September 5, 2025 earnings call, Staggs discussed SWK's sale of the majority of its royalty assets and the Mod 3 subsidiary for approximately book value. He described the remaining portfolio as $234 million in performing loans yielding 14.1% with a leaner cost structure, and stated that SWK is now focused on high-yield debt. On the Q2 2025 earnings call, Staggs reported that SWK had returned $49 million to shareholders through a $4 per share special dividend and an additional $3 million through share repurchases. He attributed a measured pace of deployments to increased capital in private credit and SWK's cost of capital, and noted that NIH scientific funding cuts had impacted some portfolio companies that are vendors into that channel.